1. Redfield M, Jacobsen S, Burnett J et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202.
2. Faris R, Flather M, Purcell H et al. Diuretics for heart failure. Cochrane Database Syst Rev 2006: CD003838.
3. Meta-Analysis Research Group in Echocardiography (MeRGE) AMI Collaborators. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation 2008; 117: 2591–8.
4. Свирида О., Овчинников А., Агеев Ф. Влияние кандесартана и его комбинации со спиронолактоном на диастолическую функцию левого желудочка и содержание биохимических маркеров баланса коллагена у пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Сердеч. недостаточность. 2010; 11: 263–75.
5. Verma S, Silke B, Hussain M et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol 1987; 10: 38–46.
6. Opie L, Kaplan N. Diuretics. Drugs for the heart (6th ed). Eds. L.Opie, B.Gersh. Elsevier Saunders 2005; p. 80–103.
7. Yamato M, Sasaki T, Honda К et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003; 67: 384–90.
8. López B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–35.
9. Uchida T, Yamanaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl. 2): 14–7.
10. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 26: 145–50.
11. Goodfriend T, Ball D, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63: 45–50.
12. Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507–13.
13. Díez J, Panizo A, Gil M et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rates: relation to myocardial fibrosis. Circulation 1996; 93: 1026–32.
14. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
15. Laurent G. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 251: C1–9.
Авторы
А.Г.Овчинников, Ф.Т.Агеев
Научно-диспансерный отдел ИКК им. А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва